Welcome to our dedicated page for Viridian Therapeutics, Inc.\DE SEC filings (Ticker: VRDN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Viridian Therapeutics, Inc.\DE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Viridian Therapeutics, Inc.\DE's regulatory disclosures and financial reporting.
Viridian Therapeutics (VRDN) launched a preliminary 424B5 for a primary offering of common stock and, in lieu of common for certain investors, Series B non-voting convertible preferred stock. Each Series B share converts into 66.67 shares of common at the holder’s election, subject to a holder‑set Beneficial Ownership Limitation between 4.9% and 19.9%. The company granted underwriters a 30‑day option to buy additional common shares. Net proceeds will support commercial launch activities for veligrotug and VRDN‑003, research and development, and general corporate purposes.
Viridian reported preliminary cash, cash equivalents and marketable securities of $490.9 million as of September 30, 2025. On October 17, 2025, it entered a Purchase and Sale Agreement with DRI for up to $300 million tied to clinical, regulatory and commercial milestones, with tiered U.S. net sales royalties of 7.5% up to $600 million, 0.8% from $600–$900 million, and 0.25% from $900 million–$2 billion. The same day, Viridian amended its Hercules facility to provide up to $300.0 million across tranches, maturing on October 17, 2030, with a floating rate capped at 9.45% and an interest‑only period through October 17, 2029 (extendable upon milestones). Common stock trades on Nasdaq as “VRDN”; Series B has no planned listing.
Viridian Therapeutics (VRDN) announced a preliminary balance of approximately $490.9 million in cash, cash equivalents, and marketable securities as of September 30, 2025. The figure is unaudited and subject to completion of financial closing procedures, and the company’s independent auditor has not performed any review or assurance work on this number. The final amount reported in the upcoming unaudited condensed consolidated balance sheet may differ materially.
Viridian Therapeutics, Inc. files an S-3ASR prospectus supplement describing its pipeline and offering mechanics. The company highlights lead programs including veligrotug (an intravenous anti-IGF-1R monoclonal antibody) and VRDN-003 (a planned low-volume, subcutaneous anti-IGF-1R intended for at-home auto-injector use for TED). The filing states VRDN-006 and VRDN-008 are engineered FcRn inhibitors. Stated timelines include VRDN-006 proof-of-concept IgG reduction data in Q3 2025, an anticipated IND submission for VRDN-008 by end of 2025, and anticipated VRDN-003 topline REVEAL-1 and REVEAL-2 data in H1 2026. As of September 3, 2025 the company had 81,668,033 common shares outstanding, 134,864 Series A and 145,160 Series B preferred shares. Use of proceeds is for development, commercialization preparation, working capital and general corporate purposes. The Registration Rights Agreement requires Viridian to use commercially reasonable efforts to register certain shares and explicitly does not include demand or piggyback registration rights.
Viridian Therapeutics (VRDN) filed an 8-K to disclose a collaboration and license agreement signed 30 Jul 2025 with Japan-based Kissei Pharmaceutical covering two IGF-1R monoclonal antibodies, veligrotug and VRDN-003, for thyroid eye disease and other potential indications in Japan. Kissei receives exclusive Japanese development and commercialization rights and a limited non-exclusive manufacturing right; Viridian retains global rights elsewhere and will supply product.
Financial terms: Kissei will pay $70 million upfront. Viridian is eligible for up to $315 million in development, regulatory and sales milestones. Tiered royalties in the low-20% to mid-30% range on future Japanese sales will follow launch. Kissei funds Japanese clinical, regulatory and commercial activities under joint-steering oversight, reducing Viridian’s cash burden.
Strategic impact: The agreement delivers immediate, non-dilutive capital, extends cash runway and externally validates VRDN-003/veligrotug while preserving all ex-Japan upside. Key execution risks include dependence on Kissei’s development success and Viridian’s ongoing manufacturing obligations.